Frontier Biotechnologies(SH:688221) Zhong Guo Jing Ji Wang·2025-03-26 02:41Core Viewpoint - Frontline Bio has reported a net loss for seven consecutive years since its IPO in 2020, with a peak fundraising of 1.8 billion yuan through UBS Securities [1][4]. Financial Performance - In 2024, the company achieved total revenue of 129.47 million yuan, representing a year-on-year increase of 13.32% compared to 114.25 million yuan in the previous year [1][3]. - The net profit attributable to the parent company was -202.02 million yuan, and the net profit after deducting non-recurring gains and losses was -336.19 million yuan [1][3]. - For 2023, the company reported total revenue of 114 million yuan, a year-on-year increase of 34.82%, with a net profit of -329 million yuan, slightly improved from -357 million yuan in the previous year [3][4]. Historical Financial Data - From 2018 to 2022, the company's revenue figures were 1.91 million yuan, 20.86 million yuan, 46.62 million yuan, 40.50 million yuan, and 84.74 million yuan, respectively [4]. - The net profits for the same period were -247 million yuan, -192 million yuan, -231 million yuan, -260 million yuan, and -357 million yuan, indicating a consistent trend of losses [4]. IPO and Fundraising - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial share price of 20.50 yuan, raising a total of 1.84 billion yuan [4][5]. - The funds raised were intended for various projects, including clinical research for HIV treatments and pain relief patches, as well as for marketing network development and working capital [5].